Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within  days prior to the first dose of study treatment. The use of physiologic doses of corticosteroids (up to .mg/d of prednisone or equivalent) may be approved after consultation with the sponsor.
Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding  mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within  days prior to the first dose of trial treatment. The use of physiologic doses of corticosteroids may be approved after consultation with the Sponsor.
Diagnosis of immunodeficiency or is receiving systemic steroid therapy (> mg of prednisone or equivalent) or any other form of immunosuppressive therapy (including immune modulators or systemic corticosteroids) that cannot be discontinued safely within  days prior to study enrollment
Patient has a diagnosis of immunodeficiency, or is receiving systemic steroid therapy (>  mg prednisone daily, or steroid equivalent) or any other form of immunosuppressive therapy within  days prior to the first dose of avelumab
Has a diagnosis of immunodeficiency or is receiving any form of immunosuppressive therapy within  days prior to the first dose of trial treatment or is taking chronic systemic steroids (in doses exceeding  mg daily of prednisone equivalent) within  days prior to the first dose of trial treatment; Note: Subjects with asthma or chronic obstructive pulmonary disease that require intermittent use of bronchodilators, inhaled steroids, or local steroid injections are not excluded from the study
Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (i.e., doses exceeding  mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within  days prior the first dose of study therapy
Patients receiving steroid treatment exceeding replacement dosing
Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding  mg daily of prednisone or equivalent) or any other form of immunosuppressive therapy within  days prior to the first dose of pembrolizumab
Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding  mg daily of prednisone equivalent) or any form of immunosuppressive therapy within  days prior to the first dose of trial treatment (with the exception of daily dexamethasone =<  mg)
Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy (in dosing exceeding  mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within  days prior to the first dose of MK-
Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding  mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within  days prior to the first dose of study drug
Participants must not have a diagnosis of immunodeficiency or is receiving systemic steroid therapy at a dose of >  mg prednisone daily or equivalent at time of first dose of trial treatment
Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy (in dosing exceeding  mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within  days prior to the first dose of trial treatment
Has a diagnosis of immunodeficiency or is receiving systemic steroid or any other form of immunosuppressive therapy within  days prior to the first dose of trial treatment therapy;\r\n* NOTE: Systemic steroid doses of ?  mg of prednisone daily or its equivalent are allowed in patients receiving physiologic replacement steroid doses
Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy (in dosing exceeding  mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within  days prior to the first dose of trial treatment.
Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding  mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within  days prior the first dose of study treatment.
Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy (>  mg prednisone daily or equivalent) or any other form of immunosuppressive therapy prior to trial treatment; patients receiving systemic steroids at physiologic doses are permitted to enroll assuming steroid dose is not above the acceptable threshold (>  mg prednisone daily or equivalent)
Has a diagnosis of immunodeficiency, is receiving systemic steroids above physiologic dose (>  mg/day prednisone or equivalent) within  days of start of therapy or is receiving any other form of immunosuppressive therapy.
Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy (at a dose greater than  mg/day of prednisone equivalent) or any other form of immunosuppressive therapy within  days prior to the first dose of trial treatment
Has a diagnosis of immunodeficiency or receiving systemic steroid therapy (in dosing exceeding  mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within  days prior to the first dose of study treatment. The use of physiologic doses of corticosteroids may be approved after consultation with the Sponsor.
Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy at a dose of >  mg prednisone daily or equivalent at time of first dose of trial treatment
Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy at a dose of >  mg prednisone daily or equivalent at time of first dose of trial treatment
Has a diagnosis of immunodeficiency or receiving steroid therapy of any other form of immunosuppressive therapy within  days prior to first dose of trial treatment; subjects who receive daily steroid replacement therapy serve as an exception to this rule; daily prednisone at doses of  to . mg (or hydrocortisone equivalent doses) is an example of replacement therapy
Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy equivalent to >=  mg/day of prednisone, or any other form of immunosuppressive therapy within  days prior to the first dose of trial treatment
Patient has a diagnosis of immunodeficiency or is receiving systemic steroid therapy(>  mg prednisone daily, or steroid equivalent) or any other form of immunosuppressive therapy within  days prior to the first dose of pembrolizumab
Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of systemic immunosuppressive therapy within  days prior to the first dose of trial treatment, with the exception of steroids for adrenal insufficiency in which case prednisone =<  mg/day or its equivalent is allowed
Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within  days prior to the first dose of trial treatment, patients with human immunodeficiency virus (HIV) adequately controlled on antiretrovirals (undetectable viral load) and patients with chronic lymphocytic leukemia (CLL) not requiring systemic treatment will be included; in addition, steroids for physiologic replacement will be allowed (must be equal to or less than mg of prednisone/day)
Administration of or condition requiring administration of systemic steroid therapy or any other form of immunosuppressive therapy within  days prior to initiating study treatment; Exception: patients with conditions that can be managed with steroids equivalent to or less than an oral prednisone dose of  mg daily would not be excluded from the study
Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within  days prior to the first dose of trial treatment; the use of physiologic doses of corticosteroids (prednisone  mg or equivalent) may be approved after consultation with the sponsor
Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding  mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within  days prior to the first dose of pembrolizumab
Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding  mg daily of prednisone or equivalent) or any other form of immunosuppressive therapy within  days prior to the first dose of MK-
Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy at a dose of >  mg prednisone daily or equivalent at time of first dose of trial treatment
Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within  days prior to initiation of lymphodepletion; exception: patients on chronic physiologic dose of steroid equivalent to prednisone <  mg/day is allowed
Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy >  mg prednisone or equivalent per day or any other form of immunosuppressive therapy within  days prior to the first dose of study treatment;
Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy in excess of prednisone  mg/ h equivalent, or any other form of immunosuppressive therapy within  days prior to the first dose of trial treatment
Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy (in dosing exceeding  mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within  days prior to the first dose of protocol specified therapy.
Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in doses exceeding  mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within  days prior to the first dose of study drug.
Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding  mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within  days prior to the first dose of study drugs. The use of physiologic doses of corticosteroids may be approved after consultation with the Sponsor.
Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding  mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within  days prior the first dose of study treatment
Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding  mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within  days prior the first dose of study treatment.
Participants with a diagnosis of immunodeficiency or who are receiving systemic steroid therapy (>= than  mg prednisone or its equivalent) or any other form of immunosuppressive therapy within  days prior to the first dose of study treatment
Has a diagnosis of immunodeficiency or is receiving systemic immunosuppressive therapy within  days prior to the first dose of trial treatment; physiologic doses of steroid therapy (=<  mg/day prednisone equivalents) is allowed
Has a diagnosis of immunodeficiency (including organ grafts and human immunodeficiency virus [HIV]), or is receiving systemic steroid therapy (in dosing exceeding  mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within  days prior to the first dose of study drug (exceptions: nasal corticosteroids, inhaled steroids, adrenal replacement steroids and steroid creams are allowed)
Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding  mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within  days prior the first dose of study medication
Has a diagnosis of immunodeficiency OR is receiving a systemic steroid therapy exceeding  mg daily dose of prednisone or equivalent or any other form of immunosuppressive therapy within  days prior to allocation, except in the case of central nervous system (CNS) metastases (see below).
Has a diagnosis of immunodeficiency or is receiving systemic immunosuppressive therapy within  days prior to the first dose of trial treatment; physiologic doses of steroid therapy (=<  mg/day prednisone equivalents) is allowed
Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (dosing exceeding  mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within  days prior to the first dose of study drug
Diagnosis of immunodeficiency or is receiving systemic steroid therapy in dosing exceeding  mg daily of prednisone equivalent or any other form of immunosuppressive therapy within  days prior to the first dose of study treatment.
Has a diagnosis of immunodeficiency or is receiving chronic steroid therapy of prednisone ?  mg daily or any equivalent dose of corticosteroids.
Has a diagnosis of immunodeficiency (HIV) or is receiving systemic steroid therapy (in excess of  mg of prednisone daily) or any other form of immunosuppressive therapy within  days prior to the first dose of trial treatment
Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding  mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within  days prior to the first dose of study treatment, or has a history of organ transplant, including allogeneic stem cell transplant
Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy (i.e., dosing exceeding  mg daily of prednisone or equivalent) or any other form of immunosuppressive therapy within  days prior to the first dose of study treatment.
Participants with a diagnosis of immunodeficiency or who are receiving chronic systemic steroid therapy (doses exceeding  mg/day of prednisone equivalent) or any other form of immunosuppressive therapy within  days prior to the first dose of study treatment. Physiologic doses of corticosteroids (up to  mg/day of prednisone or equivalent) may be used during the study
Has a diagnosis of immunodeficiency or is receiving immunosuppressive therapy within  days prior to the first dose of trial treatment; individuals who are receiving systemic steroid therapy at a stable dose less than or equal to mg of prednisone per day or its equivalent will be permitted to participate
Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding  mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within  days prior to the first dose of trial treatment. The use of physiologic doses of corticosteroids may be approved after consultation with the sponsor.
Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy (>  mg of prednisone equivalent) or any other form of immunosuppressive therapy within  days prior to the first dose of trial treatment
For Arms L (pembrolizumab) and M (nivolumab), subjects receiving chronic systemic steroid therapy (in dosing exceeding  mg daily of prednisone equivalent) or other form of immunosuppressive therapy within  days before the first dose of study treatment; use of inhaled or topical steroids or systemic corticosteroids
Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding  mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within  days prior the first dose of study treatment.
